Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

Decreased activity of cAMP responsive element-binding protein (CREB) is thought to contribute to the death of striatal medium spiny neurons in Huntington's disease (HD). Therefore, therapies that increase levels of activated CREB, may be effective in fighting neurodegeneration in HD. In this st...

Full description

Bibliographic Details
Main Authors:	Carmela Giampà, Stefano Patassini, Antonella Borreca, Daunia Laurenti, Fabrizia Marullo, Giorgio Bernardi, Frank S. Menniti, Francesca R. Fusco
Format:	Article
Language:	English
Published:	Elsevier 2009-06-01
Series:	Neurobiology of Disease
Subjects:	PDE inhibitors Rat Huntington's disease Striatum Immunohistochemistry
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996109000448

Similar Items

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease
by: Alessandro Leuti, et al.
Published: (2013-04-01)

Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity
by: Zena DeMarch, et al.
Published: (2007-02-01)

Proteostasis in striatal cells and selective neurodegeneration in Huntington’s disease
by: Julia eMargulis, et al.
Published: (2014-08-01)

Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats
by: Orsolya Kántor, et al.
Published: (2006-06-01)

BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington’s Disease
by: Vyshnavi Rallapalle, et al.
Published: (2021-05-01)

Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition
by: Francesca R. Fusco, et al.
Published: (2012-04-01)

Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington’s disease
by: S. Fernández-García, et al.
Published: (2020-05-01)

Striatal Network Models of Huntington's Disease Dysfunction Phenotypes
by: Pengsheng Zheng, et al.
Published: (2017-07-01)

Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
by: Ryoma Morigaki, et al.
Published: (2017-06-01)

Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes
by: Ella Dragileva, et al.
Published: (2009-01-01)

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
by: Zena DeMarch, et al.
Published: (2008-06-01)

Reactive Neuroblastosis in Huntington’s Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain
by: Mahesh Kandasamy, et al.
Published: (2018-03-01)

Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease
by: Irene Sebastianutto, et al.
Published: (2017-09-01)

Preserving cortico-striatal function: Deep brain stimulation in Huntington's disease
by: Sean J Nagel, et al.
Published: (2015-03-01)

Resolving pathobiological mechanisms relating to Huntington disease: Gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells
by: Hyun Ah. Kim, et al.
Published: (2014-02-01)

Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington’s Disease
by: Zhuowei Du, et al.
Published: (2017-06-01)

Restoration of the striatal circuitry: from developmental aspects towards clinical applications
by: Marie-Christin ePauly, et al.
Published: (2012-04-01)

Lentiviral delivery of Meteorin protects striatal neurons against excitotoxicity and reverses motor deficits in the quinolinic acid rat model
by: Jesper Roland Jørgensen, et al.
Published: (2011-01-01)

Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington’s disease
by: Laetitia eFrancelle, et al.
Published: (2014-09-01)

Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients
by: Marjolein Bulk, et al.
Published: (2020-01-01)

Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease
by: Qian Ma, et al.
Published: (2015-10-01)

Functional changes in neocortical activity in Huntington's Disease model mice: an in vivo intracellular study.
by: Edward A Stern
Published: (2011-06-01)

Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington’s Disease
by: Khanh Quoc Nguyen, et al.
Published: (2016-03-01)

The specific role of the striatum in interval timing: The Huntington’s disease model
by: Laurie Lemoine, et al.
Published: (2021-01-01)

Phospholipid Profiles Are Selectively Altered in the Putamen and White Frontal Cortex of Huntington’s Disease
by: Gabrielle R. Phillips, et al.
Published: (2022-05-01)

D1R- and D2R-Medium-Sized Spiny Neurons Diversity: Insights Into Striatal Vulnerability to Huntington’s Disease Mutation
by: Guendalina Bergonzoni, et al.
Published: (2021-02-01)

Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments
by: Jill R. Crittenden, et al.
Published: (2011-09-01)

Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington’s disease
by: Taylor G. Brown, et al.
Published: (2023-04-01)

Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice
by: Å. Petersén, et al.
Published: (2002-10-01)

Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease
by: Jo B. Henningsen, et al.
Published: (2021-08-01)

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
by: Johannes Burtscher, et al.
Published: (2021-09-01)

Minocycline in phenotypic models of Huntington's disease
by: Kadiombo Bantubungi, et al.
Published: (2005-02-01)

Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease
by: Jae K Ryu, et al.
Published: (2004-06-01)

Genetic Association of Phosphodiesterases With Human Cognitive Performance
by: Mark E. Gurney
Published: (2019-02-01)

Rat cortico-striatal sagittal organotypic slice cultures as ex vivo excitotoxic striatal lesion models
by: Amy McCaughey-Chapman, et al.
Published: (2022-09-01)

Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease
by: Benjamin R. Miller, et al.
Published: (2010-01-01)

CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse
by: I. Dragatsis, et al.
Published: (2009-03-01)

Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms
by: Marie-Christine Galas, et al.
Published: (2004-02-01)

Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease
by: Antonella Ferrante, et al.
Published: (2014-11-01)

Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington’s Disease
by: Emanuela Paldino, et al.
Published: (2020-10-01)